Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Open Access
- 1 November 2024
- journal article
- research article
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 17, 2829-2837
Abstract
Objective: To assess the cost-effectiveness of adding daratumumab to carfilzomib and dexamethasone (KdD) in patients with relapsed or refractory multiple myeloma (RRMM). Materials and Methods: A Markov model was established to estimate health and economic outcomes of carfilzomib and dexamethasone (Kd) with or without daratumumab for RRMM patients over a lifetime horizon. The patients and intervention of the two arms were modeled according to the CANDOR trial. Costs were collected from the Chinese health system perspective. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to evaluate the robustness of our conclusions. Results: Compared with the Kd arm, KdD achieved an additional 0.537 quality-adjusted life-years (QALYs) at an incremental cost of $138,084, resulting in an incremental cost-utility ratios (ICURs) of $257,319 per QALY. Uncertainty analyses revealed that the model is robust to all the input parameters. Conclusion: From the Chinese healthcare system perspective, adding daratumumab to the Kd regimen for patients with RRMM appears to lack cost-effectiveness. Exploring alternative avenues such as negotiating for a more favorable price or introducing a financial assistance program dedicated to daratumumab and/or carfilzomib could prove to be an effective strategy in enhancing accessibility of this combination.Keywords
This publication has 21 references indexed in Scilit:
- Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost‐effectiveness analysisAmerican Journal of Hematology, 2018
- Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple MyelomaClinical Therapeutics, 2018
- Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancerPLOS ONE, 2018
- Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United StatesJournal of Managed Care & Specialty Pharmacy, 2018
- Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United StatesExpert Review of Hematology, 2017
- Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United StatesClinical Therapeutics, 2017
- Multiple Myeloma: Diagnosis and Treatment.2017
- Social preference weights for treatments in Fabry disease in the UK: a discrete choice experimentCurrent Medical Research and Opinion, 2016
- Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspectiveJournal of Medical Economics, 2016
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012